HRP20220064T1 - Zglobno modificirani fragmenti protutijela i postupci za pripravu - Google Patents

Zglobno modificirani fragmenti protutijela i postupci za pripravu Download PDF

Info

Publication number
HRP20220064T1
HRP20220064T1 HRP20220064TT HRP20220064T HRP20220064T1 HR P20220064 T1 HRP20220064 T1 HR P20220064T1 HR P20220064T T HRP20220064T T HR P20220064TT HR P20220064 T HRP20220064 T HR P20220064T HR P20220064 T1 HRP20220064 T1 HR P20220064T1
Authority
HR
Croatia
Prior art keywords
antibody fragment
preparation
preparation according
fab
making
Prior art date
Application number
HRP20220064TT
Other languages
English (en)
Inventor
Yu-Ju G. Meng
Hok Seon Kim
Ingrid KIM
Christoph Spiess
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20220064T1 publication Critical patent/HRP20220064T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (9)

1. Pripravak koji sadržava izolirani fragment protutijela, naznačen time, da je fragment protutijela Fab izotipa IgG1 koji sadrži skraćenu zglobnu regiju koja završava ostatkom D221 (EU numeracija).
2. Pripravak prema patentnom zahtjevu 1, naznačen time, da Fab završava aminokiselinama koje sadrže aminokiselinsku sekvencu CD.
3. Pripravak prema patentnom zahtjevu 1, naznačen time, da Fab sadrži konstantnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID NO: 6 i njezine konzervativne modifikacije.
4. Pripravak prema patentnom zahtjevu 1, naznačen time, da izolirani fragment protutijela pokazuje smanjeno vezanje za FcγRIIIa, C1q ili njihovu kombinaciju.
5. Pripravak koji sadrži izoliranu nukleinsku kiselinu, naznačenu time, da kodira fragment protutijela prema patentnom zahtjevu 1.
6. Stanica domaćina, naznačena time, da sadrži pripravak prema patentnom zahtjevu 5.
7. Postupak za dobivanje protutijela, naznačen time, da obuhvaća kultiviranje stanice domaćina prema patentnom zahtjevu 6 na način da se proizvede fragment protutijela.
8. Farmaceutska formulacija, naznačena time, da sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1–4 i farmaceutski prihvatljivi nosač.
9. Pripravak prema bilo kojem od patentnih zahtjeva 1–4 za uporabu kao lijek.
HRP20220064TT 2015-10-30 2016-10-27 Zglobno modificirani fragmenti protutijela i postupci za pripravu HRP20220064T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562248792P 2015-10-30 2015-10-30
US201662346905P 2016-06-07 2016-06-07
PCT/US2016/059137 WO2017075229A1 (en) 2015-10-30 2016-10-27 Hinge modified antibody fragments and methods of making
EP16795192.0A EP3368579B1 (en) 2015-10-30 2016-10-27 Hinge modified antibody fragments and methods of making

Publications (1)

Publication Number Publication Date
HRP20220064T1 true HRP20220064T1 (hr) 2022-04-15

Family

ID=57288500

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220064TT HRP20220064T1 (hr) 2015-10-30 2016-10-27 Zglobno modificirani fragmenti protutijela i postupci za pripravu

Country Status (9)

Country Link
US (2) US10662254B2 (hr)
EP (2) EP3368579B1 (hr)
JP (3) JP6920292B2 (hr)
CN (2) CN115925962A (hr)
ES (1) ES2904553T3 (hr)
HR (1) HRP20220064T1 (hr)
PL (1) PL3368579T3 (hr)
SI (1) SI3368579T1 (hr)
WO (1) WO2017075229A1 (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254734B2 (en) * 2016-11-14 2022-02-22 Morphosys Ag Fab molecules with a rodent hinge region and a non-rodent CH1 region
WO2023212906A1 (en) * 2022-05-06 2023-11-09 Wuxi Xdc (Shanghai) Co., Ltd. Antibodis comprising engineered hinge and uses thereof
CN115873833A (zh) * 2022-11-08 2023-03-31 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
NZ556507A (en) * 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
EP1737890A2 (en) * 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
MX2007001470A (es) * 2004-08-05 2007-03-26 Genentech Inc Antagonistas anti-cmet humanizados.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2006166905A (ja) * 2004-11-17 2006-06-29 Oita Univ 狂犬病ウイルスを効果的に中和するヒトＦａｂ抗体遺伝子群
WO2009011941A2 (en) * 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
KR20080111347A (ko) * 2007-06-18 2008-12-23 이수앱지스 주식회사 암 특이적 마커에 결합하는 재조합 항체 및 그의 용도
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20110083730A (ko) * 2008-11-13 2011-07-20 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Ｃｄ37 면역치료제 병용 요법 및 이의 용도
WO2010122148A1 (en) * 2009-04-24 2010-10-28 Boehringer Ingelheim International Gmbh An improved antibody domain and antibody fragments and antibodies based thereon
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2012009704A2 (en) * 2010-07-16 2012-01-19 Avantgen, Inc. Novel peptides and uses thereof
EA027160B1 (ru) * 2011-08-17 2017-06-30 Глаксо Груп Лимитед Модифицированные белки и пептиды
KR101723273B1 (ko) * 2011-08-23 2017-04-04 로슈 글리카트 아게 2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
KR20150143458A (ko) * 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
KR102258457B1 (ko) * 2013-03-11 2021-05-31 젠자임 코포레이션 조작된 항-tgf-베타 항체 및 항원-결합 단편
EP3110845A1 (en) * 2014-02-27 2017-01-04 Allergan, Inc. Complement factor bb antibodies

Also Published As

Publication number Publication date
SI3368579T1 (sl) 2022-04-29
ES2904553T3 (es) 2022-04-05
US20180305462A1 (en) 2018-10-25
WO2017075229A1 (en) 2017-05-04
CN115925962A (zh) 2023-04-07
US10662254B2 (en) 2020-05-26
JP6920292B2 (ja) 2021-08-18
EP3368579A1 (en) 2018-09-05
CN109071674A (zh) 2018-12-21
US20200308304A1 (en) 2020-10-01
CN109071674B (zh) 2022-08-05
EP3368579B1 (en) 2021-11-24
JP2021181452A (ja) 2021-11-25
JP7413322B2 (ja) 2024-01-15
EP4036120A1 (en) 2022-08-03
JP2019504820A (ja) 2019-02-21
PL3368579T3 (pl) 2022-03-21
JP2024045138A (ja) 2024-04-02

Similar Documents

Publication Publication Date Title
HRP20201031T1 (hr) Anti-ctla-4 protutijela i postupci njihove upotrebe
HRP20211594T1 (hr) Anti-pd1 protutijela i načini uporabe
HRP20191704T1 (hr) Multispecifična protutijela
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EA202091710A1 (ru) Антитела против cd73 и способы их применения
HRP20191608T1 (hr) Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida
CY1118599T1 (el) Ανοσογονος συνθεση
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
HRP20211794T1 (hr) Humana antitijela za pd-1
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
WO2016168755A8 (en) Method for mass humanization of non-human antibodies
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
CR20230026A (es) Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
HRP20190752T1 (hr) Novo protutijelo protiv ljudskog receptora tslp
WO2016023019A3 (en) Anti-trem2 antibodies and methods of use thereof
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
NZ714320A (en) Novel antibody frameworks
AR085383A1 (es) Anticuerpos contra el il33r humano y usos de los mismos
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
WO2015161267A3 (en) Humanized and chimeric monoclonal antibodies to cd99
HRP20220064T1 (hr) Zglobno modificirani fragmenti protutijela i postupci za pripravu
MX2021004454A (es) Anticuerpos anti-sinucleina.